BeiGene
Works in Cardiovascular · Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Renal & urogenital · Respiratory · Women's health
BeiGene is a clinical trial sponsor. It has 14 active clinical trials with 3,114 planned participants, across 15 therapeutic areas. Since 2021 it has completed 91 trials and stopped 16 early.
Trial track record · since 2021
Pipeline · 14 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
3 approved drug applications with a product on the market.
Questions about BeiGene
BeiGene is lead sponsor of 14 active clinical trials on ClinicalTrials.gov, with 3,114 planned participants, in Cardiovascular, Dermatology, ENT, Genetic & rare and other areas. Since 2021 it has completed 91 trials and stopped 16 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with BeiGene; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-28.
Approve Suite is not affiliated with BeiGene.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.